Ono Pharmaceutical Co., Ltd.
OPHLFOTCHealthcare● Active
$14.55
+$0.00(+0.00%)
Market Cap$6.8B
P/E Ratio—
52W High$18.67
52W Low$9.33
Ono Pharmaceutical Co., Ltd. (OPHLF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
OPHLF · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 8, 2026EPS Actual
$0.01
Est. $0.05 · -80.8%
Revenue
$0.75B
Est. $0.71B · +5.8%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 8, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
OPHLF reports quarterly as a OTC-listed Drug Manufacturers - General company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$3.83
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$3.83
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 3, 2026 | $0.23 | — | — | — | $0.67B | — |
| ▼ Q2 FY2026 | May 8, 2026 | $0.05 | $0.01 | -80.8% | $0.75B | $0.71B | +5.8% |
| ▲ Q1 FY2026 | Feb 2, 2026 | $0.29 | $0.40 | +38.5% | $0.89B | $0.83B | +7.4% |
| ▲ Q4 FY2025 | Oct 30, 2025 | $0.27 | $0.32 | +16.4% | $0.88B | $0.83B | +5.3% |
| ▼ Q3 FY2025 | Aug 4, 2025 | $0.34 | $0.26 | -24.2% | $0.88B | $0.83B | +6.0% |
| ▼ Q2 FY2025 | May 8, 2025 | $0.09 | -$0.09 | -197.7% | $0.77B | $0.87B | -11.3% |
| ▼ Q1 FY2025 | Feb 3, 2025 | $0.27 | $0.21 | -21.1% | $0.85B | $0.83B | +2.4% |
| ▼ Q4 FY2024 | Oct 31, 2024 | $0.35 | $0.24 | -31.7% | $0.82B | $0.88B | -6.2% |
Q3 FY2026
Aug 3, 2026
EPS Actual
—
EPS Est.
$0.23
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 8, 2026Miss
EPS Actual
$0.01
EPS Est.
$0.05
EPS Surpr.
-80.8%
Revenue
$0.75B
Q1 FY2026
Feb 2, 2026Beat
EPS Actual
$0.40
EPS Est.
$0.29
EPS Surpr.
+38.5%
Revenue
$0.89B
Q4 FY2025
Oct 30, 2025Beat
EPS Actual
$0.32
EPS Est.
$0.27
EPS Surpr.
+16.4%
Revenue
$0.88B
Q3 FY2025
Aug 4, 2025Miss
EPS Actual
$0.26
EPS Est.
$0.34
EPS Surpr.
-24.2%
Revenue
$0.88B
Q2 FY2025
May 8, 2025Miss
EPS Actual
-$0.09
EPS Est.
$0.09
EPS Surpr.
-197.7%
Revenue
$0.77B
Q1 FY2025
Feb 3, 2025Miss
EPS Actual
$0.21
EPS Est.
$0.27
EPS Surpr.
-21.1%
Revenue
$0.85B
Q4 FY2024
Oct 31, 2024Miss
EPS Actual
$0.24
EPS Est.
$0.35
EPS Surpr.
-31.7%
Revenue
$0.82B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2027 | $33.75 | $35.18 | $36.68 | 1 |
| Q4 FY2026 | $44.09 | $45.95 | $47.91 | 1 |
| Q3 FY2026 | $34.49 | $35.95 | $37.48 | 1 |
| Q2 FY2026 | $32.31 | $33.68 | $35.11 | 1 |
| Q1 FY2026 | $7.96 | $8.30 | $8.65 | 1 |
| Q4 FY2025 | $43.46 | $45.30 | $47.23 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2027 | $111B | $115B | $119B | 1 |
| Q4 FY2026 | $116B | $119B | $123B | 1 |
| Q3 FY2026 | $107B | $110B | $114B | 2 |
| Q2 FY2026 | $103B | $107B | $110B | 2 |
| Q1 FY2026 | $109B | $113B | $117B | 3 |
| Q4 FY2025 | $120B | $130B | $135B | 5 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 8, 2026 | -80.8% | $14.55 | $14.55 | +0.00% |
| ▲ Q1 FY2026 | Feb 2, 2026 | +38.5% | $15.22 | $15.22 | +0.00% |
| ▲ Q4 FY2025 | Oct 30, 2025 | +16.4% | $12.20 | $12.20 | +0.00% |
| ▼ Q3 FY2025 | Aug 4, 2025 | -24.2% | $11.10 | $11.10 | +0.00% |
| ▼ Q2 FY2025 | May 8, 2025 | -197.7% | $12.75 | $12.75 | +0.00% |
| ▼ Q1 FY2025 | Feb 3, 2025 | -21.1% | $9.22 | $9.22 | +0.00% |
| ▼ Q4 FY2024 | Oct 31, 2024 | -31.7% | $11.64 | $11.64 | +0.00% |
| ▼ Q3 FY2024 | Jul 31, 2024 | -11.9% | $13.57 | $13.40 | -1.25% |
Q2 FY2026+0.00%
Report Date
May 8, 2026
EPS Beat/Miss
-80.8%
Price Before
$14.55
Price After
$14.55
Q1 FY2026+0.00%
Report Date
Feb 2, 2026
EPS Beat/Miss
+38.5%
Price Before
$15.22
Price After
$15.22
Q4 FY2025+0.00%
Report Date
Oct 30, 2025
EPS Beat/Miss
+16.4%
Price Before
$12.20
Price After
$12.20
Q3 FY2025+0.00%
Report Date
Aug 4, 2025
EPS Beat/Miss
-24.2%
Price Before
$11.10
Price After
$11.10
Q2 FY2025+0.00%
Report Date
May 8, 2025
EPS Beat/Miss
-197.7%
Price Before
$12.75
Price After
$12.75
Q1 FY2025+0.00%
Report Date
Feb 3, 2025
EPS Beat/Miss
-21.1%
Price Before
$9.22
Price After
$9.22
Q4 FY2024+0.00%
Report Date
Oct 31, 2024
EPS Beat/Miss
-31.7%
Price Before
$11.64
Price After
$11.64
Q3 FY2024-1.25%
Report Date
Jul 31, 2024
EPS Beat/Miss
-11.9%
Price Before
$13.57
Price After
$13.40
Avg Beat Reaction+0.00%
Avg Miss Reaction-0.21%
Beat Rate2 / 8 quarters
Largest Move-1.25% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: OPHLF ends December
Ono Pharmaceutical Co., Ltd. (OPHLF) most recently reported earnings on May 8, 2026 for Q2 FY2026, posting EPS of $0.01 — missing the analyst consensus of $0.05 by -80.8%. The next OPHLF earnings date is expected around September 1, 2026.
Each quarter, investors track OPHLF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. OPHLF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
OPHLF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
OPHLF earnings · 5 questionsOno Pharmaceutical Co., Ltd.'s next earnings report is expected around September 1, 2026. OPHLF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; OPHLF historically reports after market close (AMC).
OPHLF earnings datewhen is OPHLF earningsOPHLF next earnings datewhen does OPHLF report earningsOPHLF earnings calendar
▸ Source: FMP · Ono Pharmaceutical Co., Ltd. SEC filings · US GAAP · Ono Pharmaceutical Co., Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026